Search

Your search keyword '"Ostermann, Helmut"' showing total 451 results

Search Constraints

Start Over You searched for: Author "Ostermann, Helmut" Remove constraint Author: "Ostermann, Helmut"
451 results on '"Ostermann, Helmut"'

Search Results

52. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen : ICD-10 D69.3

53. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen : ICD10: D69.3

54. Sepsis in neutropenia

59. Stellungnahme zur Nutzenbewertung gemäß § 35a SGB V eines Arzneimittels für seltene Leiden (Orphan Drug), veröffentlicht am 15. Mai 2018, Vorgangsnummer 2018-02-15-D-342, IQWiG Bericht Nr. 627

60. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

61. Gemeinsame Stellungnahme der DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie und der DGI Deutsche Gesellschaft für Infektiologie zur Nutzenbewertung des G-BA von Arzneimitteln gemäß § 35a SGB V, veröffentlicht am 2. Juli 2018, Vorgangsnummer 2018-04-01-D-353, IQWiG Bericht Nr. 641

62. Leitlinie - ICD10: D69.3 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

63. Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

64. Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis

67. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

68. Candida-Reactive T Cells for the Diagnosis of Invasive Candida Infection-A Prospective Pilot Study

69. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

70. Candida-Reactive T Cells for the Diagnosis of Invasive Candida Infection—A Prospective Pilot Study

76. Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis

79. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

80. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

81. Stellungnahme zur Nutzenbewertung des IQWiG gemäß § 35a SGB V, Vorgangsnummer 2015-11-15-D-192, G-BA Bericht, veröffentlicht am 15. Februar 2016, IQWiG Bericht Nr. 360, veröffentlicht am 2. Februar 2016

82. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease

84. Functional characterization of Cereblon, the molecular target of immunomodulatory drugs

85. Geotrichum Capitatum-Sepsis In An Adult Patient With Acute Lymphoblastic Leukemia: A Case Report And Review Of The Literature

88. Treatment of invasive fungal infections in cancer patients : updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

90. Immunological Aspects of Candida and Aspergillus Systemic Fungal Infections

91. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

92. Pseudomonas aeruginosaNosocomial Pneumonia: Impact of Pneumonia Classification

93. Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma

94. Response to Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Newly Diagnosed Multiple Myeloma Is Independent of Cytogenetic Risk and Retained after Double Stem Cell Transplant

95. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain

98. Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients

99. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle

100. Lenalidomide, Adriamycin and Dexamethasone (RAD) As An Induction Regimen In Newly Diagnosed Multiple Myeloma – Interim Results From a German Multicenter Phase II Trial

Catalog

Books, media, physical & digital resources